TBI-1301 + Cyclophosphamide
Phase 1/2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Synovial Sarcoma
Conditions
Synovial Sarcoma
Trial Timeline
Sep 20, 2017 → Mar 9, 2022
NCT ID
NCT03250325About TBI-1301 + Cyclophosphamide
TBI-1301 + Cyclophosphamide is a phase 1/2 stage product being developed by Takara Bio for Synovial Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03250325. Target conditions include Synovial Sarcoma.
What happened to similar drugs?
1 of 4 similar drugs in Synovial Sarcoma were approved
Approved (1) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03250325 | Phase 1/2 | Completed |
Competing Products
8 competing products in Synovial Sarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pexidartinib | Daiichi Sankyo | Phase 2 | 39 |
| Pexidartinib | Daiichi Sankyo | Phase 3 | 44 |
| Pexidartinib | Daiichi Sankyo | Approved | 43 |
| Ramucirumab + Gemcitabine + Docetaxel | Eli Lilly | Phase 1/2 | 24 |
| LV305 + G305 | Merck | Phase 3 | 32 |
| TBI-1301 + Cyclophosphamide + Fludarabine | Takara Bio | Phase 3 | 47 |
| FHD-609 | Foghorn Therapeutics | Phase 1 | 11 |
| CFT8634 | C4 Therapeutics | Phase 1 | 11 |